Baidu
map

Prostate Cancer P D:阿比特龙和恩杂鲁胺治疗相关的副作用事件分析

2019-11-18 AlexYang MedSci原创

当新的治疗方法应用于现实情况中时,来源于临床试验的数据并不是都能够提供充分的信息来判断这些治疗方法的影响情况。最近,有研究人员分析了现实使用中与恩杂鲁胺(ENZ)和阿比特龙(ABI)相关的副作用事件情况。在EudraVigilance (EV)数据库中,研究人员鉴定了13562个ABI治疗个体案例和40599个ENZ治疗个体案例。两种药物产生的副作用事件(AEs)中,超过90%的确定为严重AEs。

当新的治疗方法应用于现实情况中时,来源于临床试验的数据并不是都能够提供充分的信息来判断这些治疗方法的影响情况。最近,有研究人员分析了现实使用中与恩杂鲁胺(ENZ)和阿比特龙(ABI)相关的副作用事件情况。

在EudraVigilance (EV)数据库中,研究人员鉴定了13562个ABI治疗个体案例和40599个ENZ治疗个体案例。两种药物产生的副作用事件(AEs)中,超过90%的确定为严重AEs。使用ABI或者ENZ治疗的年龄较大的患者(>85岁和65-85岁)的心脏、感染性、代谢和呼吸系统疾病的风险与年龄较小的患者(<65岁)相比风险增加。根据注册的III期研究数据,ABI治疗引起的最常见的副作用为肝胆疾病,而ENZ治疗最常见的副作用为精神和血管疾病。另外,EV数据库中的一些AEs并没有在注册的III期研究数据中出现。研究人员也指出了在EV数据库中有多少患者处于治疗状态是未知的。

最后,研究人员指出,EV数据库指出了注册的III期研究中未报到的AEs已经不同年龄下的AEs情况差异。临床医生应该在使用ABI或者ENZ治疗去势抵抗性前列腺癌患者时考虑这些数据。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824336, encodeId=37f118243365f, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 05 14:15:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791592, encodeId=9a581e915926d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 13:15:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364545, encodeId=522113645454a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602213, encodeId=064e160221371, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375524, encodeId=d72e3e5524c3, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Nov 19 08:04:31 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824336, encodeId=37f118243365f, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 05 14:15:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791592, encodeId=9a581e915926d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 13:15:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364545, encodeId=522113645454a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602213, encodeId=064e160221371, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375524, encodeId=d72e3e5524c3, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Nov 19 08:04:31 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824336, encodeId=37f118243365f, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 05 14:15:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791592, encodeId=9a581e915926d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 13:15:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364545, encodeId=522113645454a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602213, encodeId=064e160221371, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375524, encodeId=d72e3e5524c3, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Nov 19 08:04:31 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-20 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824336, encodeId=37f118243365f, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 05 14:15:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791592, encodeId=9a581e915926d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 13:15:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364545, encodeId=522113645454a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602213, encodeId=064e160221371, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375524, encodeId=d72e3e5524c3, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Nov 19 08:04:31 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-20 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1824336, encodeId=37f118243365f, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 05 14:15:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791592, encodeId=9a581e915926d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 13:15:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364545, encodeId=522113645454a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602213, encodeId=064e160221371, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Nov 20 14:15:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375524, encodeId=d72e3e5524c3, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Nov 19 08:04:31 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 txqjm

    谢谢了,学习

    0

相关资讯

Brit J Cancer:前列腺癌中磷脂酶D2随格林森得分蛋白表达变化研究

磷脂酶D1和D2(PLD1/2)在肿瘤发生过程中具有作用,具体是通过产生脂质磷脂酸信号和下游效应来实现。PDL1的抑制能够阻断前列腺细胞的生长和克隆的形成。最近,有研究人员调查了PLD2在前列腺癌中的作用。研究发现,PLD2蛋白在管腔和基底前列腺上皮细胞中基本等量表达。在来自于不同格林森得分的的PCa组织细胞中,PLD2蛋白表达普遍比非肿瘤组织细胞更高,并且在格林森6-8评分的PCa组织中表达增加

EMUC19:Liproca®Depot治疗前列腺癌的IIb期研究达到了主要和次要终点

在第11届欧洲泌尿外科癌症多学科大会(EMUC)上,LIDDS公司公布了Liproca®Depot治疗前列腺癌的IIb期临床试验(LPC-004试验)的最新数据。

Ann Oncol:非转移去势抵抗性前列腺癌中阿帕鲁他胺和总体存活率研究

在SPARTAN研究中,与安慰剂相比,阿帕鲁他胺加入到正在进行的雄激素阻断治疗中能够显著的延长高风险非转移去势抵抗性前列腺癌(nmCRPC)患者的无转移生存(MFS)以及到症状进展的时间。第一次中期分析(IA1)的总生存(OS)结果并不成熟,427个事件中有104个需要计划进一步进行最终的OS分析。最近,有研究人员报道了第二个预先指定的中期分析(IA2)结果。研究包括了1207名nmCRPC患者,

Oncogene:在恶性前列腺癌中HNF1B介导的SLUG抑制受EZH2抑制

前列腺癌是发达国家最常见的恶性疾病。Zeste基因增强子同源物2(EZH2)(主要的组蛋白H3赖氨酸27甲基转移酶)的过表达与前列腺癌的恶性化有关。然而,它的下游基因和途径仍旧没有很好的建立。 最近,有研究人员阐释了肿瘤抑制子肝细胞核因子1β(HNF1B)是EZH2的直接下游把基因。在前列腺癌细胞系中,EZH2能够结合到HNF1B位点并能够抑制HNF1B的表达。上述结果进一步可以由临床样本中

Cell Death & Disease:EPHB4抑制能够激活ER应激来促进前列腺癌细胞免疫原性细胞死亡

EPHB4受体在一些上皮肿瘤的发展过程中是具有作用的,并且是非常有前景的治疗靶标。在前列腺肿瘤中,EPHB4过表达并能够促进肿瘤发生。最近,有研究人员指出,EPHB4的高表达与前列腺癌患者的不良预后有关,EPHB4抑制能够在激素敏感性和去势抵抗性前列腺癌细胞中诱导细胞死亡。EPHB4抑制能够减少葡萄糖转运蛋白GLUT3的表达,影响葡萄糖的吸收并减少细胞ATP水平。上述过程与内质网膜应激的激活和肿瘤

院士指导,国产机器人完成首例前列腺癌根治术

近日,在海军军医大学附属长海医院泌尿外科孙颖浩院士亲自指导下,上海市东方医院团队利用机器人辅助腹腔镜下前列腺癌根治术,为一位65岁早期前列腺癌的男性患者成功进行了手术。手术历时约1.5小时。手术采用微创(上海)医疗机器人有限公司自主研发的图迈? Toumai?腔镜手术机器人。这是首例由国产腔镜机器人完成的前列腺癌根治术,由微创(上海)医疗机器人有限公司自主研发,图迈?腔镜机器人也成为中国首个完成高

Baidu
map
Baidu
map
Baidu
map